BioHarvest Sciences Inc (BHST)

Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener InnovationMay 18, 2026 7:00 AM
NewsfileExpanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their joint sweetener development program to include multiple plant-based sweetener molecules.The expanded collaboration builds on the initial agreement signed in 2024 and reflects strong technical progress to date, as well as Tate & Lyle's ambition to equip food and beverage manufacturers with a flexible toolkit of sweetening solutions that can be tailored to different formulation needs.As customer requirements around taste, cost and labelling continue to evolve, no single sweetener can address all food and beverage category needs. Tate & Lyle's approach focuses on developing complementary sweetening options that can be used independently or together - enabling product-specific optimisation while supporting sugar and calorie reduction goals.The collaboration draws on BioHarvest's Botanical Synthesis™ platform, which supports the development of plant-based, non-GMO ingredients, reducing the industry's reliance on traditional agricultural extraction for rare or hard-to-source botanicals. This approach aligns with Tate & Lyle's focus on delivering ingredient innovation that balances performance, scalability and responsible sourcing considerations.The partnership builds on Tate & Lyle's long-standing commitment to sugar and calorie reduction and its track record in sweetener innovation. The company's heritage includes major industry milestones, from the discovery of sucralose in 1976, to the commercialisation at scale of allulose in 2015 and high-purity bioconverted stevia Reb M in 2018.Today, Tate & Lyle's development pipeline is focused on advancing sweetening solutions that deliver great taste while supporting sugar and calorie reduction, helping customers meet evolving consumer expectations around health and wellbeing. This includes sweet ingredients that reduce sugar and calories and have the potential to support broader health and wellbeing needs. A 2025 proprietary Tate & Lyle survey across seven global markets found that over half of respondents planned to reduce their sugar consumption in the following 12 months, with strong consumer interest in great-tasting sweeteners derived from fruits and plants[1]. The intent to reduce sugar was greater than the intent to reduce calorie and fat consumption, showing how top of mind sugar reduction is for consumers.Tate & Lyle's innovation approach is informed by more than a decade of global research into consumer perceptions of ingredients. This ensures that considerations such as sensory performance, value creation and label acceptance are embedded into ingredient development from the outset.Victoria Spadaro-Grant, Chief Science and Innovation Officer at Tate & Lyle, said:"Expanding the scope of our collaboration with BioHarvest to include multiple plant-based sweetener molecules reflects the technical progress achieved to date and the aim to further expand our broad toolbox of sweetening solutions. As we define what customers ultimately look for in next-generation sweeteners - sugar-like taste, solutions anchored in nature, reduced calories and responsible use of resources - it is clear that several unmet needs in the market today are unlikely to be addressed with a single sweetener."The flexibility from the expanded collaboration with BioHarvest is critical as customers seek food and beverage category-specific solutions that balance taste, cost and labelling requirements, while supporting sugar and calorie reduction."This programme strengthens our innovation pipeline in a disciplined and efficient way and reinforces our commitment to advancing the future of sweetness through differentiated, science-led solutions."Zaki Rakib, Chief Executive Officer of BioHarvest Sciences, added: "Broadening the development program demonstrates confidence in the versatility of our Botanical Synthesis™ platform and in the progress delivered through our collaboration with Tate & Lyle. Together, we are enabling access to differentiated, plant-based sweetening solutions designed to support a range of sensory, application and economic requirements."For media enquiries, contact: tateandlyle@citypress.co.ukAbout Tate & Lyle PLC: Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day. Through our leading expertise in sweetening, mouthfeel and forti?cation, we develop ingredients and solutions which reduce sugar, calories and fat, add ?bre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings. Tate & Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 38 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet. Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2025, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2024, revenue for the enlarged Tate & Lyle Group would have been £2.12 billion. For more information, please visit www.tateandlyle.com or follow Tate & Lyle on LinkedIn, X (Twitter), Facebook or YouTube.About BioHarvest Sciences Inc: BioHarvest Sciences (NASDAQ: BHST) (FSE: 8MV) is an industrial plant cell culture company pioneering Botanical Synthesis™, a patented non-GMO platform technology that produces high-value, plant-derived compounds without growing the plant itself. By combining proprietary plant cell biology, elicitation technologies, AI-driven development and industrial-scale bioreactors, the Company creates "precision botanics" with enhanced potency, purity, consistency and commercial scalability.Backed by more than $100 million invested in its technology platform, 15 patents and multidisciplinary scientific capabilities, BioHarvest operates two complementary growth engines: a rapidly growing direct-to-consumer business and an expanding CDMO division serving pharmaceutical, nutraceutical, cosmetic, fragrance and nutrition markets. BioHarvest's platform has achieved commercial validation through VINIA®, its flagship blood flow health product, which has generated nearly $100 million in cumulative sales. The Company's CDMO business is advancing multiple high-value development programs, including rare fragrance, novel sweetener, and saffron-derived compounds, while securing long-term royalty participation opportunities through strategic partnerships.BioHarvest's proprietary Botanical Synthesis platform enables the sustainable production of scarce and highly valuable botanical compounds at industrial scale, positioning the Company at the forefront of next-generation plant-based innovation. With a growing pipeline of commercial collaborations, expanding manufacturing capabilities and increasing global industry interest, BioHarvest is establishing itself as a strategic innovation partner for companies seeking differentiated, science-driven botanical solutions.Forward-Looking StatementsThis news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on management's current expectations, beliefs, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Successful commercialization of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law. Additional information is contained in the Company's SEC filings, available at http://www.sec.gov.BioHarvest Company Contact: Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com Investor Relations Contact:Chuck Padala, Managing Director
LifeSci Advisors
chuck@lifesciadvisors.com1 Tate & Lyle Proprietary Ingredient Tracker Research - 2025 (Includes 7 Markets - US, Brazil, Germany, UK, UAE, China, and India; 1,000 respondents per marketTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/297782 Original: Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation

BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 7:00 AM
NewsfileQuarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of AprilTwo-lens framework enacted in Q1 to optimize performance across CDMO and D2C businesses Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 14, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced its first quarter 2026 financial results. The Company will hold a conference call this morning at 8:00 am Eastern Daylight Time (EDT) to discuss the results and provide an update on business operations.Dr. Zaki Rakib, Chief Executive Officer of BioHarvest, stated, "I am highly confident in the prospects of BioHarvest. We made significant progress across both sides of our business during the quarter. On the CDMO side, we successfully advanced two major Botanical Synthesis programs into Stage 2 development with combined agreements valued at over $2 million. The programs include cell bank creations for our rare fragrance and Saffron compounds. These milestones further validate the versatility and commercial potential of our Botanical Synthesis platform while expanding our future royalty and manufacturing revenue opportunities through our CDMO model." Dr. Rakib continued, "We believe BioHarvest is now approaching an important inflection point, where growth will increasingly be driven not only by VINIA manufacturing and sales, but also by the development and future production of multiple high-value plant-based compounds. This is the foundation of our "two-lens" strategy. Following last year's investments to scale our R&D infrastructure to support parallel project execution, our focus this year is on expanding the manufacturing infrastructure required to support multiple compounds at commercial scale. This focus will result in the new manufacturing site expected to be operational in the second half of 2027. Meanwhile, on the D2C side of the business, we are already seeing significant impact from our newly introduced blood flow hydration product. In Q1, we also started implementing important marketing adjustments designed to support sustainable growth with continued emphasis on improving the ratio of lifetime customer value to customer acquisition costs."First Quarter 2026 Financial Results Highlights
All figures stated in this news release are in U.S. dollars unless stated otherwise.Total revenues for the first quarter of 2026 were $8.5 million, an increase of 8% year-over-year, with gross margins of 59% of revenue compared to 58% for the same period last year.Operating loss, total, for the first quarter of 2026 was $1.8 million compared to $1.7 million for the same period of 2025. Of this amount, operating loss for the CDMO services business for the first quarter of 2026 was $1.3 million, in line with the same period of 2025, and operating loss for the D2C products business for the first quarter of 2026 was $551,000 compared to $449,000 for the same period of 2025.Total Adjusted EBITDA loss for the first quarter of 2026 was $1.2 million, in line with the same period of 2025. Adjusted EBITDA loss for the CDMO business for the first quarter of 2026 was $904,000 compared to $953,000 for the same period of 2025. Adjusted EBITDA loss for the D2C Products business for the first quarter of 2026 was $286,000 compared to $235,000 for the first quarter of 2025.Net loss for the first quarter of 2026 was $2.6 million compared to $2.3 million in the same period last year.First Quarter and Recent Operational HighlightsCDMO /Botanical Synthesis Business HighlightsIn March, BioHarvest completed Stage 1 of a multi-stage development program for a rare scent-producing plant used in the global fragrance industry. The program represents what BioHarvest believes to be the first-ever successful creation of a stable cell culture for this rare and endangered fragrance plant. This scent from this plant is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per kilogram and demand growing across the Middle East, Asia, and luxury Western perfume markets.This month, BioHarvest announced that its CDMO division signed a $1.2 million Stage 2 contract as part of a multi-stage development program for this rare scent-producing plant. This contract follows completion of Stage 1 in March, where a stable cell bank of a unique cell culture-based composition containing rare molecules was produced. At the end of Stage 2, which will take approximately six to nine months, BioHarvest will have produced enough fragrance raw material for the purpose of conducting commercial trials. Under the terms of the Stage 2 agreement with this customer, BioHarvest retains 20% ownership of the compositions successfully developed and would also earn a second source of revenue as the manufacturing entity, creating a long-term, royalty-driven economic model as the cell bank under development advances toward commercialization.Additionally, this month, our CDMO division successfully completed Stage 1 of a multi-stage development program with Saffron Tech to research, develop and commercialize bioactive compounds in saffron, one of the world's most valuable and health-promoting botanicals. SaffronTech is using BioHarvest's patented Botanical Synthesis platform to produce these compounds consistently, economically, and sustainably - and thus eliminate the need for large-scale cultivation, seasonal constraints, and geopolitical dependencies.The completion of Stage 1 has triggered the advancement to Stage 2 under this development agreement. The Stage 2 agreement is valued at over $1 million and will focus on generating enough biomass to support future pre-commercial testing and product development for nutraceutical and culinary applications.As of the first quarter, BioHarvest's VINIA manufacturing center of excellence is now incorporated into the CDMO organization to align its manufacturing capabilities under a single platform serving both the D2C products business and the Company's external CDMO partners.Direct-to-Consumer (D2C) Products Business HighlightsVINIA-Branded Wellness Products VINIA is now the number one resveratrol polyphenol brand in the USA and contributed to 95% of total sales as of the end of Q1, 2026.The VINIA Blood Flow Hydration product has achieved $920,000 in cumulative revenue realized since its launch in end November 2025. The VINIA Blood Flow Hydration product is now the number two contributor to incremental new customer sales with 20% of new customer revenue year-to-date on VINIA.com and Amazon, ahead of all other categories except VINIA capsules. As announced last quarter, BioHarvest is now pivoting the majority of its marketing budget to digital marketing efforts - a transition from primarily relying on television advertising that targeted a higher aged demographic to a stronger focus on recruiting a younger consumer base with greater disposable income with its broader VINIA portfolio of products. Dr. Rakib added, "In the first quarter, we continued to see an increased number of users for our newly introduced Blood Flow Hydration product. We believe this product will be a major contributor to our growth in 2026 and moving forward. In the first quarter we started implementing steps aimed at improving the profitability of the D2C business. We started shifting our marketing mix from TV to digital, and to a younger demographic. We are also unlocking the significant capabilities we built with our network of Health Pros who are helping us rapidly scale our Blood Flow Hydration product and provide a lower cost of customer acquisition for us."First quarter 2026 Financial Results Summary
All figures stated in this news release are in U.S. dollars unless stated otherwise.Revenues for the first quarter of 2026 increased 8% year-over-year to $8.5 million from $7.9 million.Cost of revenue was $3.5 million compared to $3.3 million for the same period last year.Gross profit in the first quarter of 2026 was $5 million, or 59% of total revenue, compared to $4.6 million, or 58% of total revenue, for the same period last year. Sales and marketing expenses totaled $4.1 million for the first quarter of 2026, compared to $3.7 million for the same period last year, to support the sales growth of the D2C business.General and administrative expenses totaled $1.4 million for the first quarter of 2026, aligned with the same period last year, but on a percentage of revenue basis, reduced to 16% of revenues, as compared to 18% in the same period last year.Total operating expenses for the first quarter were $6.9 million, compared to $6.3 million for the same quarter last year. The increase in operating expenses was primarily due to increased marketing spend and higher expenses from the CDMO services division. Net loss for the first quarter of 2026 totaled $2.6 million, or $0.11 per basic and diluted share, as compared to a net loss of $2.3 million, or $0.13 per basic and diluted share, for the same period last year. Adjusted EBITDA loss (a non-IFRS measure) totaled $1.2 million, aligned with previous period last year. Under the two-lens approach, the first quarter adjusted EBITDA losses of the CDMO Services and Products divisions are $904,000 and $286,000 respectively, as compared to $953,000 and $235,000 for the same period last year.Cash and cash equivalents, together with bank deposits as of March 31, 2026, totaled $20.2 million, compared to $3.4 million as of March 31, 2026.First Quarter 2026 Earnings Call InformationDate: Thursday, May 14, 2026Time:8:00 a.m. Eastern TimeWebcast:https://events.q4inc.com/attendee/387184352 The earnings conference call webcast will be broadcast live, and attendees are encouraged to register via the webcast link at least 10 minutes prior to the call to ensure participation.A recording of the webcast will be available for replay on the Company's website within the Investor Relations/Events & Presentations section.Use of Non-IFRS Financial MeasuresThis press release includes the following non-IFRS measure - Adjusted EBITDA, which is not a measure of financial performance under IFRS and should not be considered as an alternative to net income as a measure of financial performance. Adjusted EBITDA represents operating profit (loss) before interest, taxes, depreciation and amortization adjusted for stock-based compensation and fair value adjustment of convertible loan and or warrants, issuance of warrants as well as exchange rate impacts. The company believes this non-IFRS measure, when considered together with the corresponding IFRS measures, provides useful information to investors and management regarding financial and business trends relating to the company's results of operations. However, this non-IFRS measure has significant limitations in that it does not reflect all the costs and other items associated with the operation of the company's business as determined in accordance with IFRS. In addition, the company's non-IFRS measures may be calculated differently and are therefore not comparable to similar measures by other companies. Therefore, investors should consider non-IFRS measures in addition to, and not as a substitute for, or superior to, measures of financial performance in accordance with IFRS. A reconciliation of Adjusted EBITDA to net income, its corresponding IFRS measure, is shown below.IFRS OPERATING LOSS TO ADJUSTED EBITDA RECONCILIATIONUnaudited
In USD thousands
For the three months period ended March 31, 
20262025
CDMO Services Products Elimination of inter-segment transactionsTotalCDMO Services ProductsElimination of inter-segment transactionsTotalOperating (Loss)(1,283)(551)-(1,834)(1,270)(449)-(1,719)Depreciation and Amortization 304124-428279120-399Share Based Payment75141-2163894-132Adjusted EBITDA (Non-IFRS)(904)(286)-(1,190)(953)(235)-(1,188)(*) (*) The Adjusted EBITDA figures for the three months ended March 31, 2025, as previously reported, included finance expenses of $220 thousand. These have been excluded from the restated comparative figures presented herein in order to align with the current period's methodology and to ensure comparability between periods. Management believes this presentation more accurately reflects the Company's underlying operational performanceAbout BioHarvest
BioHarvest (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.Forward-Looking StatementsThis news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on management's current expectations, beliefs, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Successful commercialization of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured. For the Products Business Unit, launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is never an assurance that any product set will successfully disrupt established product categories, or that increased marketing spend will successfully expand demographic appeal or market share. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law. Additional information is contained in the Company's SEC filings, available at http://www.sec.gov.BioHarvest Company Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com Investor Relations Contact:
Chuck Padala, Managing Director
LifeSci Advisors
chuck@lifesciadvisors.comBioHarvest Sciences Inc. and its subsidiaries
Unaudited Interim Condensed Consolidated Statements of Financial Position
USD dollars in thousands
NoteAs of March 31,As of December 31,20262025Assets


Current assets


  Cash and cash equivalents
$ 19,167$ 23,025  Bank deposits
1,001-  Trade accounts receivable
2,1201,981  Other accounts receivable
1,061935  Inventory
4,9714,559Total current assets
28,32030,500



Non-current assets


  Restricted cash
436433  Property, plant and equipment, net
8,5508,326  Right-of-use assets, net
8,2528,406Total non-current assets
17,23817,165Total assets
$ 45,558$ 47,665



Liabilities


Current liabilities


  Trade accounts payable
$ 2,682$ 2,627  Other accounts payable
2,6312,173  Deferred revenue
474492  Lease liabilities
1,2711,405  Loans31,732149  Liability for Agricultural Research Organization6457452  Accrued liabilities
331386Total current liabilities
9,5787,684



Non-current liabilities


  Lease liabilities
10,25110,130  Loans37862,420  Liability for Agricultural Research Organization61,9201,983Total non-current liabilities
12,95714,533



Shareholders' equity


  Share capital and contributed surplus4133,217133,001  Accumulated deficit
(110,194)(107,553)Total Shareholders' equity
23,02325,448



Total liabilities and shareholders' equity
$ 45,558$ 47,665 BioHarvest Sciences Inc. and its subsidiaries
Unaudited Interim Condensed Consolidated Statements of Loss and Other Comprehensive Loss
USD in thousands, except per share data

Three Months Ended March 31,
20262025  Revenues
$ 8,507$ 7,860  Cost of revenues
(3,470)(3,265)Gross profit
5,0374,595



Operating expenses


  Research and development
(1,394)(1,245)  Sales and marketing
(4,126)(3,681)  General and administrative
(1,351)(1,388)Total operating expenses
(6,871)(6,314)



Operating loss
(1,834)(1,719)  Finance income
114-  Finance expenses
(875)(581)Net loss before tax
(2,595)(2,300)  Taxes on income
(46)(38)Net loss and comprehensive loss
(2,641)$ (2,338)



Basic and diluted loss per share
(0.11) (0.13)Weighted average number of shares outstanding
22,667,36517,327,716 BioHarvest Sciences Inc. and its subsidiaries
Unaudited Interim Condensed Consolidated Statements of Cash Flows
USD in thousands
Three Months Ended March 31,
20262025Cash flows from operating activities:

  Net loss$ (2,641)$ (2,338)Adjustments to reconcile net loss to net cash used in operating activities:

  Depreciation and Amortization428399  Interest over Liability for Agricultural Research Organization5770  Finance expense (income), net552299  Share based compensation216132Adjustments for changes in working capital:

  Change in Trade accounts receivable(139)(360)  Change in Other accounts receivable(135)(59)  Change in Inventory(412)(357)  Changes in Trade accounts payable, Other accounts payable and Accrued liabilities712563  Changes in deferred revenue(17)224Net cash used in operating activities(1,379)(1,427)


Cash flow from investing activities:

  Purchase of property and equipment(593)(684)  Deposit of restricted cash for bank guarantee, net of drawing-4  Deposits placed in short-term bank deposits(1,000)-Net cash used in investing activities(1,593)(680)


Cash flow from financing activities

  Repayments of lease liabilities(507)(221)  Repayments of loans (principal and interest)(198)-  Repayment of royalties' liability to the Agricultural Research Organization(105)-  Proceeds from loans-3,343  Payments of finder fees(30)-Net cash (used in) provided by financing activities(840)3,122


  Exchange rate differences on cash and cash equivalents(46)(4)  Increase (decrease) in cash and cash equivalents(3,812)1,015  Cash and cash equivalents at the beginning of the period23,0252,390Cash and cash equivalents at the end of the period$ 19,167$ 3,401


Supplemental disclosure of significant non-cash transactions:

  Recognition of right-of-use assets and lease liabilities127-


Supplemental disclosure of cash flow information:

  Taxes paid-- To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297459 Original: BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

BioHarvest Sciences Appoints New Head of Business Development for its CDMO DivisionMay 13, 2026 5:32 PM
NewsfileBusiness development appointment is aligned with securing long-term customers for development and manufacturing partnershipsVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceutical, nutrition, and cosmetic areas for BioHarvest's contract development and manufacturing organization (CDMO) business.Photo: Ms. Nedira Salzman-FrenkelTo view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6168/297382_f1227e55d4093b4e_002full.jpg"We are pleased to welcome Nedira to our team to lead business development for BioHarvest's CDMO, aligned with our strategy of building long-term partnerships with customers," Dr. Zaki Rakib commented. "Nedira brings over a decade of experience in the life sciences industry, including securing contracts with pharmaceutical companies and other related sectors. She has strong experience leading licensing deals, operational scaling, and building cross-functional teams. Nedira will work closely with me to deliver on our revenue targets, in line with our anticipated growth and the launch of our new facility next year."Previously, Ms. Salzman-Frenkel was Vice President of Business Development at an Israeli biotech, where she spearheaded BD efforts, resulting in a binding licensing term-sheet with a top global pharmaceutical company for Phase 3 clinical development. Prior to this, Ms. Salzman-Frenkel was CEO of the Salzman Group, a global pharmaceutical and contract research organization (CRO) that was focused on pre-clinical and clinical development of novel, small-molecule therapeutics, while providing services to the pharmaceutical, medical device, and agrochemical industries. During her tenure, Ms. Salzman-Frenkel secured approximately $30 million dollars in CRO contracts across these industries. Prior to this, Ms. Salzman-Frenkel co-founded Beetlebung Pharma Ltd. and Solviva, as well as led business development efforts at Salzman Capital Ventures, Ltd., a firm providing full-service pharmaceutical support, custom laboratory research and development, and drug development consultation. Ms. Salzman-Frenkel commented, "I am excited to join BioHarvest at such an important stage, particularly as demand continues to increase for innovative and sustainable CDMO solutions. BioHarvest's Botanical Synthesis platform represents a differentiated approach to the development and manufacturing of plant-derived bioactive compounds, and I look forward to expanding strategic partnerships and commercial opportunities across multiple industries. Leveraging my experience in drug development and business strategy, I aim to drive BioHarvest's continued growth."Ms. Salzman-Frenkel has a Master of Business Administration from Tel Aviv University, a Master of Science in Biochemistry from Hebrew University of Jerusalem and a Bachelor of Science in Life Sciences from Ben Gurion University. About BioHarvest
BioHarvest (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.Forward-Looking StatementsThis news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on management's current expectations, beliefs, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. For the CDMO Services Business Unit, there is no assurance that the company will obtain expanded business partnerships and commercial opportunities, and readers are cautioned that additional future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law. Additional information is contained in the Company's SEC filings, available at http://www.sec.gov.BioHarvest Company Contact: Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com Investor Relations Contact:Chuck Padala, Managing Director
LifeSci Advisors
chuck@lifesciadvisors.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/297382 Original: BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division

BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary ApplicationsMay 13, 2026 8:00 AM
Newsfile- CDMO program advances to Stage 2 of development agreement valued at $1.125 million-Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals- In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Columbia and Rehovot, Israel---(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has completed Stage 1 under a multi-stage development agreement, successfully establishing a stable saffron cell bank for potential nutraceutical and culinary applications. The development partner is SaffronTech, a company pioneering advanced cultivation methods for saffron, one of the world's most valuable and health-promoting botanicals. Completion of Stage 1 has triggered the advancement to Stage 2 under an ongoing development agreement, which will now focus on utilizing BioHarvest's patented Botanical Synthesis™ platform to generate enough biomass to support future pre-commercial testing and product development for nutraceutical and culinary applications. The stable saffron cell bank created in Stage 1 demonstrates a molecular profile representing saffron's key bioactive compounds, including crocin, picrocrocin, and safranal, associated with saffron's sensory characteristics and well researched multiple health attributes.Dr. Zaki Rakib, Chief Executive Officer and Executive Chairman of BioHarvest Sciences, commented, "Completion of Stage 1 represents another important validation of the versatility of our Botanical Synthesis platform to create sustainable cell banks from scarce botanicals. Saffron is one of the world's most expensive and scientifically researched plants, yet its traditional supply chain faces major sustainability, ethical, and scalability limitations. By establishing stable saffron cell cultures containing the plant's key bioactive compounds, we have demonstrated the potential to produce saffron-derived ingredients that can eventually be scaled to meet significant existing unmet market demand. This milestone further supports the evolution of our CDMO business model, where BioHarvest participates in the downstream value creation of products developed using our platform."Michael Oster, CEO of SaffronTech, commented, "We are extremely encouraged by the successful completion of Stage 1 and the scientific progress achieved by BioHarvest. This milestone validates the potential of Botanical Synthesis to redefine how saffron-based ingredients can be produced sustainably, ethically, and consistently for both health-focused and culinary markets. We look forward to advancing the program into the next stage of development."About Saffron as a Nutraceutical and Culinary CompoundSaffron is widely regarded as one of the most valuable agricultural ingredients in the world, often commanding prices ranging from approximately $3,000 to more than $10,000 per kilogram depending on quality and origin. Demand is driven by both culinary applications and the rapidly growing nutraceutical and wellness sectors. Industry estimates suggest that annual global saffron production is only approximately 500 to 600 metric tons, with the majority produced in Iran, where escalating geopolitical tensions often lead to significant market volatility and supply chain instability.While the 2025 global saffron market is estimated at nearly $500 million annually*, the broader nutraceutical categories associated with saffron's researched bioactive properties represent an estimated 2025 total addressable market of over $100 billion globally. These include rapidly growing segments such as mood and stress support, cognitive health, sleep quality, antioxidant activity, and metabolic wellness. In addition, saffron remains a highly prized culinary ingredient used globally across premium food, beverage, flavoring, and specialty gastronomy applications, where consistent quality and supply stability are increasingly important for a segment which represents more than 50% of the total market demand.BioHarvest's Agreement with SaffronTech and its Role in the Sustainable Production of SaffronBioHarvest believes its Botanical Synthesis platform creates a highly differentiated and sustainable solution for the future production of saffron compositions by enabling the production of saffron-derived compounds without traditional farming, harvesting, or dependence on geographic and climate limitations. The process also provides the potential for enhanced consistency, purity, scalability, and long-term supply stability for both food-grade and nutraceutical-grade applications.Under the terms of the agreement, BioHarvest retains 25% ownership of the saffron composition being developed through the multi-stage program. Additionally, BioHarvest will earn manufacturing royalties from any future saffron compound that is produced on its Botanical Synthesis platform, reflecting BioHarvest's strategy to, where possible, participate downstream in the future value creation of products developed using its Botanical Synthesis platform. With Stage 1 completed, BioHarvest and SaffronTech are advancing toward Stage 2, where the saffron cells stored in the proprietary cell bank will be propagated in liquid medium bioreactors to generate significant biomass to support future pre-commercial testing, formulation development, and validation.BioHarvest believes the saffron development program further strengthens the positioning of its CDMO division as a differentiated platform capable of addressing some of the world's most valuable and supply-constrained plant-derived compounds through sustainable biotechnology solutions, while expanding the Company's pipeline of potential royalty-generating partnerships.*Grandview Research - Saffron Market Size, Share & Trends Analysis Report (2026 - 2033)
https://www.grandviewresearch.com/industry-analysis/saffron-marketForward-Looking StatementsThis news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on management's current expectations, beliefs, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Successful commercialization of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is never an assurance that any product set will successfully disrupt established product categories. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law. Additional information is contained in the Company's SEC filings, available at http://www.sec.gov.BioHarvest Company Contact: Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com Investor Relations Contact:Chuck Padala, Managing Director
LifeSci Advisors
chuck@lifesciadvisors.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/297297 Original: BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications

BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis PlatformMay 12, 2026 7:30 AM
NewsfileSource plant is widely regarded as one of the most valuable fragrance raw materials in the worldStage 2 contract follows successful Stage 1 completion in March 2026Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 12, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has signed a $1.2 million-dollar Stage 2 contract as part of a multi-stage development program for a rare scent-producing plant used in the global fragrance industry. This scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per kilogram and demand growing across the Middle East, Asia, and luxury Western perfume markets.This contract is subject to a non-disclosure agreement which prevents the disclosure of the other party and the targeted plant compounds, and follows completion of Stage 1 in March 2026, where a stable cell bank of a unique cell culture-based composition containing rare molecules was produced. At the end of Stage 2, which will take approximately six to nine months, BioHarvest will have produced enough of the fragrance raw material for the purpose of conducting commercial trials. Under the terms of the Stage 2 agreement with this customer, BioHarvest retains 20% ownership of the compositions successfully developed and would also earn a second source of revenue as the manufacturing entity, creating a long-term, royalty-driven economic model as the cell bank under development advances toward commercialization. CEO of BioHarvest Sciences Dr. Zaki Rakib, commented, "A Stage 2 contract means that we have crossed the tallest technological hurdle of this unprecedented research and development journey. It also means we can be ready for production in the second half of 2027, in tandem with an increase in manufacturing capacity due to the planned commissioning of a new production facility. This milestone also brings BioHarvest closer to entering the growing premium fragrance segment, estimated to represent a $23 billion-dollar market opportunity within the global $58.9 billion scents and fragrances industry1." The Major Principal of the partner firm, which is a prominent United Arab Emirates-based investment group, commented, "We have gladly awarded BioHarvest this contract after being highly encouraged by the successful completion of Stage 1. Soon, we will be initiating our commercialization program designed to bring the product to market in the second half of 2027."Dr. Rakib added, "This contract is expected to serve as a catalyst for engaging additional potential customers in other future fragrance programs using BioHarvest's Botanical Synthesis platform. We believe that the unique scalable capability of our technology significantly expands the addressable market opportunity for our CDMO division and strengthens our long-term royalty-driven growth strategy."Sources:(1) Grand View Research - Fragrance Market Report (2026-2033)
https://www.grandviewresearch.com/industry-analysis/fragrances-marketAbout BioHarvest
BioHarvest (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.Forward-Looking StatementsThis news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on management's current expectations, beliefs, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Successful commercialization of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is never an assurance that any product set will successfully disrupt established product categories. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law. Additional information is contained in the Company's SEC filings, available at http://www.sec.gov.BioHarvest Company Contact: Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com Investor Relations Contact:Chuck Padala, Managing Director
LifeSci Advisors
chuck@lifesciadvisors.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/297104 Original: BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform

BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial ResultsMarch 31, 2026 4:02 PM
NewsfileFY2025 Revenues were $34.5 million, up 37% vs previous year.The VINIA brand has achieved the No.1 resveratrol polyphenol position in the United States Market*.Successful 4Q2025 Institutional-led Financing raised gross proceeds of an oversubscribed $19.9 million. Cash and cash equivalents of $23 million as of December 31, 2025.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced its fourth quarter and full-year 2025 financial results. The Company will hold a conference call today after market close at 4:30 pm Eastern Daylight Time (EDT) to discuss the results and provide an update on business operations.Fourth Quarter 2025 revenues were $9.1 million, within guidance range, up 25% year-over-year with full year revenue achieving $34.5 million, up 37% vs previous year.Fourth Quarter 2025 gross margins were at 58%, up 100 bps over the same period last year, with full year Gross Profit at 59%, + 400 basis points vs previous year.Cash and cash equivalents of $23 million as of December 31, 2025.The VINIA brand has achieved the No.1 resveratrol polyphenol position in the United States Market*Successful fourth quarter launch of VINIA Blood Flow Hydration™, the first hydration solution powered by the blood flow benefits of VINIA's piceid resveratrolAchieved significant milestone with completion of Stage 1 for a rare scent producing plant used in the global fragrance industry.Organization focus-driven alignment for optimizing the performance of the growth engines of the company: D2C product business and Contract Development Manufacturing Organization (CDMO).Management GuidanceGuidance for 2026 full year revenue for the D2C Business is in the range of $38-$42 million with an estimated positive adjusted EBITDA range of $0.5 million - $2 million.For full-year 2026, management expects to be in the range of $4 million to $6 million, representing approximately 2x to 3x growth versus 2025 CDMO revenue. Following the successful launch of the CDMO and reflecting our confidence in its long-term growth potential, we plan to make significant investments in the business in 2026. As a result, CDMO Adjusted EBITDA is expected to be a loss of approximately $4- $5 million for the year. Including intercompany sales of VINIA powder from the CDMO to the Products business, total 2026 CDMO revenue is expected to be in the range of $12 million to $14 million. Guidance for 2026 Full Year Consolidated Revenue is in the range of $42-48 million with the D2C Business contributing $38-$42 million and CDMO contributing $4-$6 million. Adjusted EBITDA loss for the year is estimated to be ($3-$4 million).Mr. Ilan Sobel, Chief Executive Officer of BioHarvest, stated, "2025 was a year of strong execution, commercial validation, and continued capability-building across both our D2C products business and CDMO services platform. We drove significant growth in our consumer business. We expanded our customer base and reinforced our leadership in the resveratrol category. We secured anchor partnerships across multiple CDMO verticals, further validating the strength, scalability, and versatility of our platform. We aligned the organization behind our two growth engines to further optimize their operations.Mr. Sobel continued, "Equally important, we strengthened our financial profile, and have delivered an annualized revenue run rate exceeding $36 million and gross margins approaching 60%. Following the successful financing initiatives completed in late 2025, the company possesses the cash resources sufficient to fund its planned operational activities and obligations for at least 12 months from this date today." Fourth Quarter 2025 and Full Year Operational Highlights
All figures stated in this news release are in U.S. dollars unless stated otherwise.Full-year 2025 revenues increased 37% year-over-year to $34.5 million, with gross margins expanding by 400 basis points versus previous year to 59% of revenue. Total revenues for the fourth quarter of 2025 increased by 25% year-over-year to $9.1 million, within management guidance, with gross margins expanding by 100 basis points versus previous year, to 58% of revenue. The Company continued to realize a high degree of operating leverage in the fourth quarter, with total operating expenses reduced from 80% of total revenue to 70% of total revenues year over year.Adjusted EBITDA loss for Q4 of ($536K) vs ($1.8 million) in Q4-24 and FY-25 ($3.6 million) vs FY-24($5.9 million)Overall fourth quarter net loss was $2.2 million compared to $3 million in the same period last year.In September, the Company announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, fortifying the Company's balance sheet with an additional $10.9 million in gross proceeds and a concurrent $3.8 million reduction in total debt.In November, the Company completed its first institutional financing, raising gross proceeds of an oversubscribed $19.9 million.Direct-to-Consumer (D2C) Products Division (VINIA-Branded Wellness Products) Highlights Total VINIA® active users surpassed 85,000 as of March 2026, with $84 million of cumulative revenue realized since launch. In 2025, BioHarvest expanded its "VINIA inside" product portfolio: In November 2025, the Company launched VINIA Blood Flow Hydration™, the first hydration solution powered by the blood flow benefits of VINIA's Piceid resveratrol to enter the $17 billion-dollar North America, electrolytes drink market**. In June 2025, introduced VINIA Daily 2X Chews™, an Informed Sport-certified product, and the first-of-its-kind chew designed to increase nitric oxide production and arterial dilation, and to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles. BioHarvest's new product launch of VINIA Blood Flow Hydration has achieved strong initial uptake in the U.S. market since its fourth quarter launch and is now the number two contributor to incremental new customer sales with 15% of New Customer Revenue year-to-date on VINIA.com, ahead of all other categories except VINIA capsules. As such, the Company will continue to accelerate marketing investment in 2026 behind this product. Botanical Synthesis Contract Development and Manufacturing Organization (CDMO) Services Division Highlights In 2025, BioHarvest secured new, significant contract partnerships based on BioHarvest's patented Botanical Synthesis platform: In May 2025, announced a development and commercial partnership targeting the multi-billion-dollar fragrance and scents market, to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss.In May, announced the first successful Stage 1 CDMO partner contract has moved to Stage 2, which involves the delivery of a sufficient amount of biomass to be tested for suitability and involves the development of optimal growing conditions in liquid media.In September, announced the ability to produce plant-based exosomes at scale, in its bioreactor media, demonstrating a new capability within its Botanical Synthesis platform and a potential source of future product and CDMO revenue streams.In October 2025, announced a development and commercial partnership with Saffron Tech, a pioneer in revolutionizing advanced cultivation methods for saffron - one of the world's most valuable and health-promoting botanicals - to develop and commercialize saffron-derived botanical compounds.In the fourth quarter of 2025 and first few months of 2026, the CDMO division continued to make significant progress across existing projects including completing Stage 1 for a rare scent-producing plant used in the global fragrance industry. The program represents what BioHarvest believes to be the first-ever successful creation of a stable cell culture for this rare and endangered fragrance plant and positions BioHarvest to enter the growing premium fragrance segment, estimated at $23B globally.***Dr. Zaki Rakib commented "Since its creation in 2024, the CDMO has evolved beyond a traditional model in what we can describe more as partnerships with its customers. This shift reflects the collaborative nature of our engagements, where we often participate in long-term value creation, including royalties and, in certain cases, ownership in developed compositions. It also reflects the additional investments we are making in the form of building new capabilities that include AI- driven molecule discovery and exosomes production. This and the consumer products business form two separate growth engines, that requires a two-lens approach to maximize the Company's ability to generate value." Fourth Quarter 2025 Financial Results Summary
All figures stated in this news release are in U.S. dollars unless stated otherwise.Revenues for the fourth quarter of 2025 increased 25% to $9.1 million - within management guidance. The increase was largely attributable to growth in the VINIA® franchise, which exceeded 85,000 active users as of March 2026. Gross profit increased 27% to $5.2 million, or 58% of total revenue, in the fourth quarter of 2025, as compared to $4.1 million, or 57% of total revenue, in the same year-ago quarter. The increase in gross margin was primarily attributable to the benefits of revenue mix, increased manufacturing scale and improved manufacturing yields. Total operating expenses for the fourth quarter totaled $6.3 million, as compared to $5.8 million compared to the same quarter last year. The increase in operating expenses was primarily due to increased marketing spend and higher expenses from the CDMO services division. Total operating expenses shrunk on a percent-of-revenue basis to 70% of revenue, as compared to 80% in the same year ago quarter. Net loss for the fourth quarter of 2025 totaled $2.2 million, or $0.1 per basic and diluted share, as compared to a net loss of $3.0 million, or $0.17 per basic and diluted share, for the same period last year. Adjusted EBITDA loss - a non-IFRS measure - totaled $0.5 million, as compared to an Adjusted EBITDA loss of $1.8 million for the same period last year. Cash and cash equivalents as of December 31, 2025, totaled $23.0 million, as compared to $2.4 million as of December 31, 2024. Fourth Quarter and Full Year 2025 Earnings Call Access Information
Date: Tuesday, March 31, 2026
Time: 4:30 PM Eastern Time
Webcast link: https://events.q4inc.com/attendee/512060117The conference call will be broadcast live and will be available for replay on the Company's website within the Investor Relations/Events & Presentations section. Please access the webcast link at least 10 minutes ahead of the conference call to ensure timely participation.*This #1 Resveratrol Polyphenol brand position is based on comparing VINIA® 2025 annual sales revenue in the US with the estimated market size for Resveratrol Nutritional Supplements, utilizing NielsonIQ (NIQ) 2025 market projections for Resveratrol Nutritional Supplements and Beverages, together with Amazon sales data projections for Resveratrol Nutritional Supplements, which represent the large majority of the Total Resveratrol Polyphenol Only Market. ** Fortune Business Insights: Electrolyte Drinks Market Size, Share & Industry Analysis.
Source: https://www.fortunebusinessinsights.com/electrolyte-drinks-market-113794*** Grand View Research - Fragrance Market Report (2026-2033)
Source: https://www.grandviewresearch.com/industry-analysis/fragrances-marketAbout?BioHarvest
BioHarvest (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit?www.bioharvest.com. Use of Non-IFRS Financial Measures This press release includes the following non-IFRS measure - Adjusted EBITDA, which is not a measure of financial performance under IFRS and should not be considered as an alternative to net income as a measure of financial performance. Adjusted EBITDA represents net income (loss) before interest, taxes, depreciation and amortization adjusted for stock-based compensation and fair value adjustment of convertible loan and or warrants, issuance of warrants as well as exchange rate impacts. The company believes this non-IFRS measure, when considered together with the corresponding IFRS measures, provides useful information to investors and management regarding financial and business trends relating to the company's results of operations. However, this non-IFRS measure has significant limitations in that it does not reflect all the costs and other items associated with the operation of the company's business as determined in accordance with IFRS. In addition, the company's non-IFRS measures may be calculated differently and are therefore not comparable to similar measures by other companies. Therefore, investors should consider non-IFRS measures in addition to, and not as a substitute for, or superior to, measures of financial performance in accordance with IFRS. A reconciliation of Adjusted EBITDA to net income, its corresponding IFRS measure, is shown below. IFRS NET INCOME (LOSS) TO ADJUSTED EBITDA RECONCILIATION
(Unaudited)
(U.S dollars in thousands)Three-month period ended December 31, 20252024     Net (loss)($2,204)($2,956)Depreciation and Amortization433341Taxes(64)8Interest, net & Finance Charges428609Fair Value adjustment of derivative liability -Convertible loan-21Share Based Payment149146Exchange rates impact and interest over leases (IFRS 16)686-Other exchange rate impact 36-Adjusted EBITDA (Non-IFRS)($536)($1,831) Forward-Looking Statements Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Successful commercialization of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is never an assurance that any product set will successfully disrupt established product categories. There is no assurance that the Company will maintain or improve current financial performance, as revenues and margins are dependent on a combination of factors such as supply chain efficiencies, input cost stability, marketing efficiencies and uncertain consumer preferences. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. BioHarvest Company Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.comInvestor Relations Contact:
Chuck Padala, Managing Director
LifeSci Advisors
chuck@lifesciadvisors.comBioHarvest Sciences Inc. and its subsidiaries
Consolidated Statements of Financial Position
USD dollars in thousandsAs of December 31,As of December 31,20252024AssetsCurrent assetsCash and cash equivalents$23,025$2,390Trade accounts receivable1,9811,116Other accounts receivable935695Inventory4,5593,655Total current assets30,5007,856  Non-current assets  Restricted cash433371Property, plant and equipment, net8,3267,750Right-of-use assets, net8,4069,024Total non-current assets17,16517,145Total assets$47,665$25,001  Liabilities  Current liabilities  Trade accounts payable$2,627$3,525Other accounts payable2,1733,609Deferred revenue492906Lease liabilities1,405772Loans1493,905Liability for Agricultural Research Organization4521,140Accrued liabilities386401Total current liabilities7,68414,258  Non-current liabilities  Lease liabilities10,1309,141Loans2,420-Liability for Agricultural Research Organization1,983272Total non-current liabilities14,5339,413  Shareholders' equity  Share capital and contributed surplus133,00197,748Accumulated deficit(107,553)(96,418)Total Shareholders' equity25,4481,330  Total liabilities and shareholders' equity$47,665$25,001 BioHarvest Sciences Inc. and its subsidiaries
Consolidated Statements of Loss and Other Comprehensive Loss
USD in thousands, except per share dataYear Ended December 3120252024Revenues$34,508$25,188Cost of revenues(14,032)(11,246)Gross profit20,47613,942  Operating expenses  Research and development(5,312)(4,797)Sales and marketing(15,812)(11,733)General and administrative(4,927)(4,401)Total operating expenses(26,051)(20,931)  Operating loss(5,575)(6,989)Finance income54-Finance expenses(5,538)(5,916)Net loss before tax(11,059)(12,905)Taxes on income(76)(8)Net loss and comprehensive loss(11,135)$(12,913)  Basic and diluted loss per share(0.60)(0.80)Weighted average number of shares outstanding18,411,15316,193,787 BioHarvest Sciences Inc. and its subsidiaries
Consolidated Statement of Cash Flows
USD in thousandsYear Ended December 3120252024Cash flows from operating activities:Net loss$(11,135)$(12,913)Adjustments to reconcile net loss to net cash used in operating activities:  Depreciation and Amortization1,6241,251Fair value adjustments of Convertible Loans-3,503Fair value adjustments of derivative liability - Warrants-408Re-assessment of Liability for Agricultural Research Organization(396)(205)Interest over Liability for Agricultural Research Organization270403Finance expense (income), net3,756823Share based compensation597601Adjustments for changes in working capital:  Change in Trade accounts receivable(865)(308)Change in Other accounts receivable(240)(286)Change in Inventory(904)(1,189)Changes in Trade accounts payable, Other accounts payable and Accrued liabilities4821,040Changes in deferred revenue(415)188Net cash used in operating activities(7,226)(6,684)  Cash flow from investing activities:  Purchase of property and equipment(2,355)(2,835)Deposit of restricted cash for bank guarantee, net of drawing(10)(192)Net cash used in investing activities(2,365)(3,027)  Cash flow from financing activities  Repayments of lease liabilities(1,382)(579)Proceeds from loans12,4023,417Repayments of loans (principal and interest)(5,772)(103)Repayments of Convertible Loans (principal and interest)-(693)Proceeds from exercise of investor warrants, net of finder fees6,800-Net proceeds from issuance of units of securities in private placement-4,330Repayment of royalties' liability to the Agricultural Research Organization(159)-Net proceeds from issuance of shares in public offering18,262-Proceeds from exercise of stock options36408Net cash provided by financing activities30,1876,780  Exchange rate differences on cash and cash equivalents39(34)Increase (decrease) in cash and cash equivalents20,596(2,931)Cash and cash equivalents at the beginning of the period2,3905,355Cash and cash equivalents at the end of the period$23,025$2,390  Supplemental disclosure of significant non-cash transactions:  Conversion of convertible loans into equity7,60320,527Exercise of investor warrants by settlement of an outstanding debt1,759-Reclassification of warrants as an equity instrument-934Purchase of property under installment payment agreement-1,440Recognition of right-of-use assets and lease liabilities3998,351  Supplemental disclosure of cash flow information:  Taxes paid3945 To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290705
Original: BioHarvest Sciences Reports Fourth Quarter and Full-Year 2025 Financial Results

BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis PlatformMarch 31, 2026 8:00 AM
NewsfileCDMO division has successfully completed Stage 1 under a development contractVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has successfully completed Stage 1 of a multi-stage development program for a rare scent-producing plant used in the global fragrance industry. The program is being conducted under a contract signed approximately one year ago, and represents what BioHarvest believes to be the first-ever successful creation of a stable cell culture for this rare and endangered fragrance plant.This milestone positions BioHarvest to enter the growing premium fragrance segment, estimated to represent a $23B market opportunity within the global $58.9B scents and fragrances industry*. This particular scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per kilogram and demand growing across the Middle East, Asia, and luxury Western perfume markets.Ilan Sobel, CEO of BioHarvest Sciences, commented, "This first-ever achievement marks a major breakthrough for BioHarvest and represents a significant expansion into one of the most valuable segments of the global fragrance industry. Successfully creating stable cell cultures for such a unique plant demonstrates the power of our Botanical Synthesis platform and reinforces our ability to unlock rare, high-value plant-derived molecules at industrial scale. This milestone also strengthens our royalty-driven CDMO model and creates long-term value opportunities for our shareholders."The development was achieved using BioHarvest's proprietary Botanical Synthesis Platform Technology, which enables the production of rare plant-derived fragrance compounds without the need to cultivate or harvest the original plant, which is classified as an endangered species and typically grows only in highly specific regions of Southeast Asia. The rare molecules responsible for the scent and aroma of this highly coveted plant, including sesquiterpenes and chromones, were successfully identified in the Stage 1 cell cultures, with molecular profiles closely matching those found in the original plant. This achievement demonstrates the ability of BioHarvest's platform to replicate highly complex plant-based fragrance compositions, that include but not limited to the terpene's family of molecules, previously considered difficult or impossible to reproduce sustainably. Sesquiterpenes are natural plant compounds that help keep plants protected from environmental challenges. They are of interest for use in fragrances because they evaporate slowly, and as such they act as the base-notes giving scents their depth and a long-lasting aroma.Under the terms of the stage 1 agreement, BioHarvest retains 20% ownership of the compositions developed through this multi-stage program, creating a long-term royalty-driven economic model as development advances toward commercialization. This structure aligns with BioHarvest's evolution from a traditional CDMO to a Partner Development and Manufacturing Organization (PDMO), where the company participates directly in downstream value creation.The Major Principal of this partner firm, which is a prominent United Arab Emirates -based investment group**, commented, "We are highly encouraged by the successful completion of Stage 1 and the progress achieved by BioHarvest. This milestone validates both the scientific strength of the Botanical Synthesis platform and the commercial potential of sustainable plant-derived fragrance compositions. We look forward to advancing to Stage 2 and ultimately bringing these rare and valuable fragrance ingredients to global markets."With Stage 1 now completed, BioHarvest is ready to advance to Stage 2, where cells stored in a proprietary cell bank will be propagated in liquid medium to generate significant biomass. Once stage 2 commences, this biomass is expected to be available for pre-commercial testing within 6 to 9 months, with full development and industrial-scale manufacturing anticipated within 12 to 18 months. Importantly, this development is expected to serve as a template for multiple future fragrance programs using BioHarvest's Botanical Synthesis platform. The successful creation of stable cell cultures containing complex fragrance molecules demonstrates the company's ability to systematically target additional rare and high-value fragrance plants, potentially unlocking a pipeline of development programs across premium fragrance categories. BioHarvest believes this capability significantly expands the addressable market opportunity for its CDMO division and strengthens its long-term royalty-driven growth strategy.*Grand View Research - Fragrance Market Report (2026-2033) 
https://www.grandviewresearch.com/industry-analysis/fragrances-market** This CDMO project contains a Non-Disclosure Agreement that includes both the name of the partner and of the targeted plant compoundsAbout?BioHarvest
BioHarvest (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit?www.bioharvest.com. Forward-Looking Statements Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Successful commercialization of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is never an assurance that any product set will successfully disrupt established product categories. There is no assurance that the Company will maintain or improve current financial performance, as revenues and margins are dependent on a combination of factors such as supply chain efficiencies, input cost stability, marketing efficiencies and uncertain consumer preferences. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. BioHarvest Company Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com Investor Relations Contact:
Chuck Padala, Managing Director
LifeSci Advisors
chuck@lifesciadvisors.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/290629
Original: BioHarvest Sciences Announces First-Ever Successful Stable Cell Culture Development of Rare Fragrance-Producing Plant Using Proprietary Botanical Synthesis Platform

BioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United StatesMarch 26, 2026 7:30 AM
NewsfileVINIA's leadership position in the market validates its superior arterial dilation and blood flow performance as well as BioHarvest's Botanical Synthesis platform technologyVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 26, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that its VINIA® brand has achieved the position of the #1 Resveratrol Polyphenol Nutraceutical Brand in the United States*.VINIA's leadership position is driven by its clinically demonstrated ability to increase arterial dilation, improving blood flow and enabling enhanced delivery of oxygen and nutrients throughout the body. This mechanism of action addresses what many medical experts increasingly recognize as one of the most foundational elements of human health and performance: efficient blood flow and oxygen delivery."Achieving the No.1 position in the U.S. resveratrol category in less than five years reflects both the strength of VINIA and the power of our Botanical Synthesis platform technology," said Ilan Sobel, Chief Executive Officer of BioHarvest Sciences. "VINIA's clinically demonstrated ability to increase arterial dilation, providing blood flow benefits, combined with its unique protected plant-cell delivery system, create a differentiated product that consumers are increasingly recognizing and adopting. The strength of VINIA as a subscription base product has enabled us to build unique and credible e-commerce platform capabilities with our VINIA.com website which accounts for approximately 80% of VINIA US revenue."VINIA's leading position in the market reflects the continued growth of the Company's direct-to-consumer business, which generated more than $30 million in U.S. revenue for full-year 2025 and approximately $85 million in global cumulative revenue to date. Less than five years after entering the U.S. market, VINIA has achieved category leadership, with more than 85,000 active users of VINIA wellness products across the United States and Israel.Dr. Edward Maristany, member of the BioHarvest Scientific Advisory Board and Functional Medicine Physician, commented "VINIA is a life-changing compound — which has impressive solubility, bioavailability and efficacy qualities given the unique structure of the compound and the protective cell envelope which also shields the compound from degradation as it moves through our body. I have over 200 patients who have consistently taken VINIA for more than a year. The improvements in their quality of life derived from VINIA's clinically proven ability to increase arterial dilation have been significant. The effects of improved blood flow have been substantial in driving improvements in my patients' physical energy and mental alertness."Botanical Synthesis- The Technology Behind the VINIA BrandVINIA is built around a proprietary red grape composition featuring piceid resveratrol as its hero molecule, combined with a complex of naturally occurring grape polyphenols including catechin, quercetin, anthocyanins, and tannins. These molecules work synergistically to support arterial function and vascular performance.The effectiveness of this composition is further enhanced by BioHarvest's proprietary Botanical Synthesis technology, which preserves the molecules inside their natural plant cell environment. This protective cell envelope safeguards the phytonutrients from degradation during production through to ingestion as well as during passage through the stomach's acidic environment, helping preserve efficacy.Unlike traditional plant extracts that isolate individual molecules, Botanical Synthesis delivers a naturally derived, patentable, non-GMO composition that preserves the original molecular conformation of phytonutrients within their native cellular environment — creating a differentiated delivery system for plant-based compounds.With VINIA, BioHarvest's Botanical Synthesis platform magnifies the piceid resveratrol levels by up to 100x compared to what is naturally found in red grapes, while maintaining the synergy of the full polyphenol complex.Due to VINIA's vasodilation benefits and ability to improve blood flow, the Company views VINIA as a foundational compound to be added to other synergistic molecules to create innovative and effective nutraceutical products, further strengthening BioHarvest's leadership in plant-based health solutions.*This #1 Resveratrol Polyphenol brand position is based on comparing VINIA® 2025 annual sales revenue in the US with the estimated market size for Resveratrol Nutritional Supplements, utilizing NielsonIQ (NIQ) 2025 market projections for Resveratrol Nutritional Supplements and Beverages, together with Amazon sales data projections for Resveratrol Nutritional Supplements, which represent the large majority of the Total Resveratrol Polyphenol Only Market.About BioHarvest Sciences Inc.BioHarvest (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.Forward-Looking StatementsInformation set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. Launching new products is not certain, may take significant time, and is subject to risks and uncertainties beyond company control such as consumer preferences, competition landscape, government approvals required for sale or import, acceptance of benefit claims, and marketing budgets of the company and its competitors. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com Investor Relations Contact:
Chuck Padala, Managing Director
LifeSci AdvisorsTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/290040
Original: BioHarvest Sciences Announces that VINIA is Now the No.1 Resveratrol Polyphenol Brand in the United States

BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026March 17, 2026 8:30 AM
NewsfileVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 17, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide an update on business operations.Fourth Quarter and Full Year 2025 Earnings CallDate: Tuesday, March 31, 2026
Time: 4:30 PM Eastern Time
Webcast link: https://events.q4inc.com/attendee/512060117The Earnings call webcast will be broadcast live, and attendees are encouraged to register via the webcast link at least 10 minutes prior to the call to ensure timely participation. The webcast recording will be available for replay on the Company's website within the Investor Relations/Events & Presentations section. About BioHarvest Sciences
BioHarvest (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.Forward-Looking StatementsInformation set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. Forward-looking statements include those set forth in the Risk Factors section of the Company's Securities and Exchange Commission (SEC)'s filings which can be found within the Investor Relations section on the Company's website, or on the SEC's website at http://www.sec.gov.BioHarvest Corporate Contact:
Dave Ryan
(604) 622-1186
info@bioharvest.com Investor Relations Contact:
Chuck Padala, Managing Director
LifeSci Advisors
chuck@lifesciadvisors.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/288805
Original: BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026

BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi LevyMarch 5, 2026 7:30 AM
NewsfileVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately.Mr. Tsur has served on BioHarvest's Board since 2021 and has contributed meaningfully to the Company's strategic development and governance during a period of operational expansion, capital formation, product commercialization, and market positioning.Zaki Rakib, Chairman of BioHarvest, commented, "On behalf of the Board and management team, I would like to sincerely thank David for his leadership, experience and dedication over the past four years. His wisdom and guidance have supported BioHarvest's growth and strategic evolution. We are grateful for his contributions and wish him continued success."Prof. Hezi Levy joins the Board with decades of leadership experience across Israel's healthcare system, recognized globally as one of the world's most advanced. A physician by education, Prof. Levy previously served as Director General of the Israeli Ministry of Health, including during the COVID-19 pandemic, where he played a central role in guiding national healthcare policy during a period of exceptional challenge.Figure 1. Professor Hezi LevyTo view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6168/286354_6c280e8ba47ecbd3_001full.jpgProf. Levy also served as Head of the Medical Corps of the Israel Defense Forces (IDF) with the rank of Brigadier General and was the General Manager of Barzilai Medical Center for many years, overseeing one of Israel's major hospitals and complex healthcare operations.Chairman Zaki Rakib added, "We are honored to welcome Prof. Levy to the BioHarvest Board. His deep medical expertise, executive leadership and experience managing large healthcare systems will add significant strength to our governance as we execute our scaling of our direct-to-consumer products business while advancing our high-value biotechnology CDMO platform."About BioHarvestBioHarvest (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.Forward-Looking StatementsInformation set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. Launching new products is not certain, may take significant time, and is subject to risks and uncertainties beyond company control such as consumer preferences, competition landscape, government approvals required for sale or import, acceptance of benefit claims, and marketing budgets of the company and its competitors. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.Contacts: BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286354
Original: BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy

BioHarvest Sciences Virtual Investor Webinar | Sep 10, 2025



OBV has turned up nicely this year.

https://schrts.co/yCVipIGX

Mis read the vote form too accustomed to the cannabis stocks I will wait and see….

Mis read the vote form too accustomed to the cannabis stocks I will wait and see….

I will be selling my bioharvest sciences shares. When directors are given special status and are also able to set their salary AND are the auditors I am out!

CNVCF changed to BHST. Moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

I find it very strange how this company is overlooked. I am good with it, lets me get more at a good price. So many opportunities right now. I wish I had more $ to invest

The reverse split is timely if they are looking to uplist. With cannabis being shifted to schedule 3 I see this as an excellent move. I hope the market sees what I see

Thank you for the update

CNVCF: effective June 3,2024 a one for 35 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

I prefer they walk before they run. Pleased with the improvements. Get the share price up organically not through consolidation.
https://markets.qtrade.ca/news/story?t=iKXJizM-dSY,RBgdWBB-F545YeUB8Z65joEjuF4_Nb5o&article=4e71cccf72d47418#4e71cccf72d47418

So happy to be funding the enlightenment. Hopefully others will come along too, it is getting lonesome lol!

They have positioned themselves well. Pivoted to their other products while the bumps on the path to cannabis legalization get smoothed out. Very eager for the future

It will be cash flow positive this quarter. This is very rare for a micro cap company.

While everyone got shaken out of the cannabis space, the good companies just kept on working
https://markets.qtrade.ca/news/story?t=iKXJizM-dSY,RBgdWBB-F545YeQE_ZC_i3ESEqGOaXkD&article=56fb7bf8e99d1d77#56fb7bf8e99d1d77

New update they have been very busy

I like to back companies that do what they say they will
Royal Emerald Pharmaceuticals is a #California-based U.S. DEA & FDA-registered manufacturer/supplier of non-addictive #cannabis products being developed for medical, scientific & research purposes. We're extremely proud to be partnering with them!#biotech https://t.co/idppATIy9E— BioHarvest Sciences Inc. (@BioHarvestBHST) November 16, 2022

$CNVCF BioHarvest Sciences Inc. Announces Live Quarterly Shareholder Update Event July 7, 2022, at 2:00 PM ETPress Release | 06/24/2022

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 24, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or "the Company") invites its shareholders and the general public to join a Live Video Conference ("Webinar") on Thursday, July 7, 2022, at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).

BioHarvest Sciences CEO Ilan Sobel will host the event, which will include coverage of Q2 sales results and a detailed progress update on the 2022 Growth Priorities, with specific focus on the VINIA scale-up progress in the USA and on the Company's Cannabis market entry strategy into North America.

"We have reached the midpoint of 2022, which will be remembered as a transformative year in BioHarvest Science's growth," states CEO Ilan Sobel, adding "This year we have already made key additions to our leadership team and reached major scientific milestones - I am very excited to discuss our progress on the VINIA USA scale-up, to provide a high level update on strategic partnership discussions with key players in the North American Cannabis landscape, and to share my thoughts with our Bioharvest shareholder partners on how our disruptive platform technology will reshape the future of the Cannabis industry in North America."

The presentation will be approximately 45 minutes, followed by a live question and answer session. All shareholders, media, and interested investors are welcome to join. All registrants will be emailed a recording of the session. Any questions regarding the event can be sent to justin@bioharvest.com.

Register for free at: Q2 2022 BioHarvest Sciences Inc. Shareholder Update | BioHarvest Sciences (livestorm.co)

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6168/128834_9fd6d70f6470694a_001full.jpg

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit:www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Facebook Twitter Linkedin Youtube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis, whether in North America or other global markets. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion are subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/128834

Good hire
Target $4 / share .. 24 months

$CNVCF BioHarvest Sciences Hires Dr. Brian S. Cornblatt as Chief Medical OfficerPress Release | 05/31/2022

Vancouver, British Columbia, and Rehovot, Israel--(Newsfile Corp. - May 31, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") has hired Dr. Brian S. Cornblatt as its Chief Medical Officer, marking a significant milestone in the Company's route for the development of next generation therapeutic solutions including botanical drugs.

Dr. Cornblatt has served as Director of Consumer Clinical Research and Science and as Medical Director at Nutramax Laboratories Consumer Care, Inc. In this role Dr. Cornblatt developed novel nutraceutical formulations, designed both in vitro and clinical studies in support of products, and summarized both supporting laboratory and clinical research for healthcare workers and consumers. His most recent development has been a novel line of products (and 18 related clinical trials) which deliver the essential ingredients needed to support the production of sulforaphane, a phytochemical with many emerging indications. Dr. Cornblatt is also the inventor of three issued patents and four pending provisional patents focused on plant-based bioactive compounds and health promotion.

Prior to moving to Nutramax Laboratories in 2010, Dr. Cornblatt was the Scientific Director and Developer of the Catholic Health Initiatives' (CHI) Center for Translational Research (CTR), a combined molecular research laboratory, national biorepository, and diagnostics laboratory. The CTR supported research initiatives throughout CHI's forty Oncology centers.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6168/125931_9eab594d94ac6b7c_002full.jpg

Dr. Brian S. Cornblatt

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/125931_9eab594d94ac6b7c_002full.jpg

Dr. Cornblatt is a Johns Hopkins University School of Medicine Graduate with a Ph.D. in Pharmacology and Molecular Sciences and a postdoctoral fellowship from the Johns Hopkins Bloomberg School of Public Health, Environmental Health Sciences Division of Toxicology.

"We are delighted to welcome Dr. Cornblatt to the leadership team at BioHarvest at a time of transition and growth for us," said BioHarvest CEO Ilan Sobel. "He will help us lead the charge as we take steps to actively expand our line up of clinically based nutraceutical products and move into medicinal prescription products with our polyphenol-based products and Cannabis product line up."

Dr. Cornblatt said "I am excited about the opportunities that BioHarvest has in the medicinal space based on the CELLicitation™ technology. Some of the existing products can already form a potential for future botanical drugs and I am looking at expanding the indications for which unique products like VINIA® can be used. I look forward to working with the capable R&D team to bring to the world unique, clinically based therapeutic solutions."

BioHarvest is seeking to receive authorization in Israel to produce Cannabis for commercial purposes and is also looking to expand production facilities to North America. BioHarvest recently announced that it has produced a meaningful amount (10 kilograms) of full-spectrum Cannabis biomass at a commercial scale without growing the plant itself. (For full illustration, Watch this video or visit https://bioharvest.com. It is the first time that any group - in either industry or academia - has successfully produced meaningful quantities of full-spectrum Cannabis biomass without growing the plant itself. The Cannabis biomass is not genetically modified and was produced using the Company's proprietary BioFarming technology platform, which grows plant cells in their natural structure in proprietary bioreactors. The company has also recently (May 12) unveiled the profile of its unique Cannabis composition. It contains major and minor cannabinoids as well as terpenes.

BioHarvest has a market capitalization of approximately CAD$131M and has raised over CAD$ 58M to date. The Company holds unique patented technology that allows it to produce a unique grade of full spectrum, consistent, and clean Cannabis biomass in industrial-scale bioreactors with manufacturing costs which are significantly below industry benchmarks. Its offering will consist of multiple unique Cannabis compositions selected based on specific indications and B2B customer requirements.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

For further information, please contact:
Investor Relations
Phone: 778.686.3855
Email: info@bioharvest.com

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. There is no assurance that the ability to produce a commercial sized biomass will result in the Company entering into commercial production of Cannabis. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives. Obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured. There is no assurance the company will successfully expand its lineup of nutraceutical products or move into medical prescription products. Successful completion of these objectives will require additional financing, successful marketing initiatives, and certifications which are subject to uncertainty. In addition, prescription drug products require clinical trials which may be lengthy and expensive and have uncertain results. There is no assurance that the company will be approved for commercial Cannabis production in Israel or elsewhere. Obtaining such approvals is subject to many risks and uncertainties, in addition to the need for financing, including potential delays, unexpected changes in requirements and unexpected failure to meet requirements.

All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125931

I sure would like to see some photos of the shop, the vats , please…even a nice “walk thru” video of our production facilities would be so welcome…??

Al / Farmpride

The word is getting out about Vinia for the heart..
..

$CNVCF BioHarvest Sciences Unveils Profile of Unique Cannabis CompositionPress Release | 05/12/2022

Full spectrum profile to include major and minor Cannabinoids as well as Terpenes
Unique trichome structure provides for potentially higher solubility and bio-availability
With Trichomes representing 93% of the Cannabis biomass produced using the proprietary Bio-Plant CELLicitation™ technology, taste bitterness is significantly reduced

Vancouver, Canada, and Rehovot, Israel--(Newsfile Corp. - May 12, 2022) - BioHarvest Sciences Inc. the (CSE: BHSC) ("BioHarvest" or the "company") today unveiled the composition profile of its full-spectrum Cannabis produced in large-scale industrial bioreactors based on its proprietary Bio-Plant CELLicitation™ platform technology.

On December 8th, 2021, BHSC became the first company ever to announce that it could produce Cannabis biomass without growing the plant itself. The revealing of the unique composition profile of its first product comes as BioHarvest gears up for potential Cannabis commercialization - optimizing the manufacturing process, perfecting measurement techniques, transitioning the 2-ton/year facility to Cannabis and applying for the necessary regulatory approvals.

Reliable testing and measurements demonstrate that the composition profile includes the Cannabinoids THC, CBD, CBG, THCV, CBDV and CBC, as well as the Terpenes Beta-caryophyllene, Beta-panasinsene and Selina. While other minor Cannabinoids are present, their identity determination requires further work on the measurement techniques as the current conventional ones are not advanced enough to deal with such a distinctive Cannabinoids profile. The profile and ratio between the various Cannabinoids found in BioHarvest's product is unique and sets a path for both potential patentability and applicability to address medical indications such as ADHD, pain management and anxiety. For further protection of BioHarvest's IP and to secure patentability, more quantitative information about the profile will be revealed before September 15th, 2022. In the interim, the company confirms with certainty the significance of THC, CBD and CBG quantities inside the unique Cannabis composition.

"These achievements are remarkable and demonstrate the ability to produce unique and consistent Cannabis compositions that would have been impossible using conventional agriculture," said Prof. Zohar Kerem, Head of the Food Chemistry Labs of the Robert H. Smith Faculty of Agriculture, Food and Environment of the Hebrew University of Jerusalem. "I have been closely watching the application of BioHarvest's Bio-Plant CELLicitation™ technology to Cannabis, and I am confident that advanced analysis techniques will become available soon to further unveil the Cannabinoids richness of the unique BioHarvest's compositions."

One of the special characteristics of this Cannabis product is that it is made of trichomes representing 93% of the biomass. Trichomes are the plant's natural "mini-factories" that produce the active Cannabis ingredients (Cannabinoids, terpenes and other phytochemicals). Unlike conventional Cannabis products where a significant part of the biomass includes other parts of the flower which have a bitter taste, BioHarvest's product is primarily composed of trichomes. This significant reduction of bitterness renders the product easier to integrate in food and beverage applications.

Moreover, the unique conformation of our trichomes (amalgamated in a coral shape structure) may provide for enhanced solubility and bio-availability of the product. This would allow administration of lower doses to achieve the same desired effects, which would otherwise require a higher quantity in the case of conventionally cultivated Cannabis products.

"Our consistent, clean and efficacious Cannabis, produced with the highest ESG credentials and capital efficiency, has received a significant boost with the latest conclusive composition profile information," said CEO Ilan Sobel. "This rich full-spectrum combination of Cannabinoids and Terpenes with unique ratios is very promising for addressing medical conditions otherwise treated by synthetic drugs with significant negative side effects. The reduced bitterness taste and the potential improved solubility of our products amount to a game-changer for integration of full-spectrum Cannabis into the food & beverage industry."

BioHarvest plans to bring its first Cannabis products to market in 2022 and will be converting the current VINIA® 2-tons/year facility in Rehovot, Israel to produce Cannabis. This is happening as a result of the transition of all VINIA ® manufacturing to the new 20-ton/year facility in Yavneh, Israel.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured. There is no assurance of patentability of the Company's products. Obtaining patents is a lengthy process subject to many uncertainties. The ability of the Company's product to address medical indications in a manner different from other Cannabis products can only be determined after the process of clinical trials, the outcome of which cannot be assured.

In particular there is no assurance the company will obtain a production license or bring its first Cannabis products to market in 2022.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/123755

$CNVCF Bioharvest Sciences Inc. Successfully Completes Cannabis R&D ProgramPress Release | 03/23/2022

Now producing Cannabis biomass in large scale industrial bioreactors under the current R&D license.
Commencing the process of transitioning the current Israeli Cannabis R&D license to a production license.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 23, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") today announced that it has produced Cannabis Biomass in large scale industrial bioreactors, which represents the completion of the Company's Cannabis R&D program.

On December 8th, 2021, BHSC became the first company ever to announce that it could produce Cannabis biomass without growing the plant itself. Building on that breakthrough, the Company has made significant progress, and has now produced Cannabis in large scale industrial bioreactors, marking the start of the transition to commercial scale manufacturing. To that end, the Company has commenced the process to obtain a production license in Israel for its Cannabis products to complement the R&D license it has used to date for the Cannabis development program.

Dr. Yochi Hagay, CTO, said "I am elated and proud of this achievement. The R&D team has relentlessly pursued this moment, which marks a new era for the Cannabis industry. Our proprietary and unique amalgamated trichome structure has proven resistant to shear forces applied during the cell growth process in liquid media and it will demonstrate more advantages when it comes to the medicinal application of our products. I have never doubted our ability to use our CELLicitation technology to produce Cannabis without the need to grow the plant itself and we have broken biological barriers to grow high performance trichomes in liquid suspension. We are now ready to bring our first unique Cannabis compositions to the world. We will of course continue to invest in Cannabis R&D to add more Cannabis products to the portfolio, appreciate the IP assets and drive even further manufacturing efficiencies."

BioHarvest plans to bring its first Cannabis products to market in 2022 and will be converting the current VINIA® 2 tons/year facility in Rehovot, Israel to produce Cannabis. This is happening in conjunction with the transition of all VINIA ® manufacturing to the new 20 tons/year facility in Yavneh, Israel, which will support the scaling of successful sales of VINIA® in the US and beyond.

Ilan Sobel, CEO, states "Our unprecedented achievements present a great opportunity for the Cannabis industry. Consistent, clean, and efficacious Cannabis that is produced with the highest ESG credentials and capital efficiency with significantly lower manufacturing costs is the revolution this industry needs to gain further market traction and trust by the regulators worldwide. Our CELLicitation platform technology is a true market disruptor, cementing BioHarvest's position as a leader in plant cellular biology. With the completion of the initial Cannabis R&D program, more focus can now be applied towards achieving the desired scale for our two business verticals, Polyphenols/Antioxidants and Cannabis."

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.

In particular there is no assurance the company will obtain a production license or bring its first Cannabis products to market in 2022.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Sorry my math sucks
They are expanding from 2 to 20 multiple times a year.. so 10 times increase multiple times a year..

Company right now around 120 mil

I couldn’t tell you sales numbers but IMO their cannabis operation alone could support a 120 mil Valuation..

And Vinia is going to be wildly succesful

My timing is horrible sometimes.. so don’t listen to me making money on stocks.. the biggest benefit anyone can get is taking this product…
If I had my Trivesta up and running this would be a stock evEry Christian would buy at least three shares in..
Anavex and Bioharvest.. Annovis too..
Those would be my first Trivesta!

Bioharvest is expanding their capacity not just 20 times.. they are expanding their capacity 20 times multiple times a year!

It’s a turning point

That is what attracted me to this company. They are already producing in large quantity. Now they are expanding operations. To me it is the right product at the right time

Bioharvest pumping out extraordinary
Resveratol..

I was just going over old online news… finding postings back to 2008 showing “we” where ready to build plants and produce in …”the next quarter”. Here, and looking forward again.. to a new quarter. (2014 in New York?)
I love this idea, WE could become the number one grower / producer of so many products. Is ideas like this that will feed millions, not just printed or formed “crap”, but real food…just …when ? One other Prayer over our future.. let’s not be sold on only growing HIGH DOLLAR PRODUCT. The world needs high quality foods, at common food prices…not just pricy “space-food” or more overpriced CBD oil…excetera . ….so….WHEN?

$CNVCF BioHarvest Sciences Inc. Engages Thunder11 as a Public Relations Agency of Record
Press Release | 02/10/2022
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 10, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) (OTC PINK: CNVCF) (FSE:8MV) ("BioHarvest" or "the Company") a fast-growing Biotech firm listed on the Canadian Securities Exchange, has engaged the award winning New York City-based communications firm Thunder11 for Public Relations services.

Thunder11, which has specializations in technology, healthcare, and public affairs, will be involved in raising BioHarvest's profile with media relations, partners, and other influential audiences. BioHarvest joins a roster of Thunder11 clients which over the years has included some of the world's leading technology companies and healthcare organizations.

In January 2022, BioHarvest announced its plan to build a production facility in Canada as part of the global expansion of its Cannabis vertical. BioHarvest also recently announced it has also moved its production of full-spectrum Cannabis biomass to industrial scale bioreactors, a critical final step in ensuring adequate production levels for commercialization. This full spectrum, fertiliser free, non-genetically modified biomass is based on the company's proprietary BioFarming technology.

"We are delighted to be working with BioHarvest to tell the world the story of their breathtaking innovations, including the production of Cannabis without growing the plant," said Thunder11 Managing Partner Dan Perry. "Such innovation is not only disruptive in a good way but has tremendous potential for humanity's health and wellness as well as global sustainability."

Thunder11 offers its clients a broad range of capabilities from messaging and brand identity to thought leadership, content creation, crisis and issues management and communications and sales force training. The firm was recognized in 2019 as "Boutique PR Firm of the Year" at the Platinum PR Awards and in 2020 was named to the Agency Elite Top 100 list of leading communications agencies.

Thunder11 is led by Senior Partner Marco Greenberg, a former managing director at Burson-Marsteller and author of the 2020 Wall Street Journal bestseller "Primitive: Tapping the Primal Drive That Powers the World's Most Successful People." Marco's first PR firm worked with Akamai Technologies several years from inception through IPO. He later helped lead communications for Datto through their acquisition by Vista Equity Partners, among many other fortune 500 companies.

Greenberg co-founded Thunder11 in 2007 with Liel Leibovitz, a former NYU communications professor, host of the award-winning podcast "Unorthodox," and an author of several books including "A Broken Hallelujah: Rock and Roll, Redemption, and the Life of Leonard Cohen." Tel Aviv-based Perry was the former top editor of the Associated Press in Europe, Africa and the Middle East and the author of several books on Israel. The firm's leadership includes SVP Client Relations Ryan Birchmeier, who leads the BioHarvest account.

BioHarvest joins the many companies Thunder11 has represented, from small to large cap and Fortune 500 organizations, as well as universities, major regional healthcare systems, tech and biotech startups, venture capital firms and public affairs campaigns. In recent years, several Thunder11 clients have been named to Fast Company's Most Innovative Companies and World Changing Ideas lists and TIME's Best Inventions. Its clients have appeared everywhere from SXSW to CES from Web Summit to Aspen Ideas Festival, and among other prestigious stages around the world.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

$CNVCF BioHarvest Sciences Inc. Plans to Build a Production Facility in Ontario to Serve the Canadian Market with Unique Cannabis Products
Press Release | 01/20/2022
Vancouver, British Columbia, and Rehovot, Israel--(Newsfile Corp. - January 20, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") has announced its plan to build a production facility in Canada, as part of the next phase in the global expansion of its Cannabis vertical. To that end, the Company is exploring opportunities to acquire an existing licensed facility or a Licensed Producer (LP), which would enable the Company to use its BioFarming technology to produce and then sell unique cannabis products into the Canadian market.

The Company is pleased to announce that it has also moved its production of full-spectrum Cannabis biomass to industrial scale bioreactors, which is a critical final step in ensuring adequate production levels for commercialization. This full spectrum, pesticide free, non-genetically modified biomass is based on the Company's proprietary BioFarming technology that produces Cannabis without growing the plant itself.

Following the news release on December 8, 2021, where the Company announced that it was the first to produce a significant amount of full spectrum, non GMO Cannabis biomass without growing the Cannabis plant itself, the Company has moved swiftly towards the final stage of the development program by now growing the Trichome cells in industrial scale bioreactors. The Trichome cells contain Cannabinoids such as CBD, THC, as well as other compounds that grow naturally in the Cannabis plant. This stage successfully tested the resilience of BioHarvest's proprietary "amalgamated Trichome cells" against the shear forces generated by the large bioreactor's liquid media motion. These amalgamated Trichomes have a coral shaped structure and have a density of up to 200 times greater than the conventional agriculture case. To view the first video footage of our Cannabis biomass, visit www.bioharvest.com/investors.

Ilan Sobel, CEO of BioHarvest, said, "Our BioFarming technology not only enables the production of full-spectrum Cannabis without growing the plant but also creates unique new patentable and consistent compositions that will have corresponding human utility value. I am excited about the opportunity to bring such unique Cannabis solutions to the Canadian market by building a local production facility in Canada. To that end, we have started the engagement for finding an adequate facility and/or acquiring an existing LP who has the appropriate licenses."

BioHarvest is asking those LP's who are interested in a collaborative agreement regarding this announcement to send requests to partnership@bioharvest.com.

All interested media and investors are invited to attend an 'Introduction to BioHarvest' webinar on January 26, at 11 am PST. The event will include a live Question and Answer session. Please register here: https://app.livestorm.co/st-financial/introduction-to-bioharvest?type=detailed

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets including bio-space and exposing our technology to different verticals. There is no assurance that the ability to produce a commercial sized biomass will result in the Company entering into commercial production of Cannabis. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured. There is no assurance that the Company will be successful in acquiring a licensed facility in Canada. Health Canada approvals are required for transfers of production licenses which may take considerable time and cannot be assured. There is also no assurance that Health Canada will accept the Company's unique bioreactor production method. Production requirements in Canada are strict and require adherence to many requirements regarding safety, security and production methods and standards. Although the company is confident that its production methods will meet or exceed all standards there can be no assurance that Heath Canada will accept the Company data within a reasonable time or at all.

All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

That explains the price drop :) they are selling the news :)

$CNVCF BioHarvest Sciences Reports Double-Digit Q4 Sales Orders Growth in First Full Year of VINIA Sales
Press Release | 01/06/2022
17% quarter-over-quarter growth with record VINIA® global sales orders in Q4 of USD 825k
485% year-over-year growth with total sales orders of USD 2.4M in 2021
Continued success in VINIA® US pilot with USD 325k in sales orders in Q4, a 27% growth over Q3
Vancouver, British Columbia, and Rehovot, Israel--(Newsfile Corp. - January 6, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") today announces another strong quarter of sales growth for VINIA®, its nutrient-rich red grape supplement created through the Company's proprietary BioFarming technology, in both Israel and the United States. The USD 825k of sales orders in Q4 from its direct-to-consumer ecommerce business represents a 17% increase over Q3 and are triple the sales orders from the same quarter in 2020. VINIA® sales orders in 2021 amounted to USD 2.4M, a nearly sixfold increase over 2020.

In Israel, where VINIA® is becoming synonymous with cardiovascular health and wellness, BioHarvest reported record sales orders of USD 501k in Q4, representing growth of 11% over Q3 and 84% over Q4 2020 - and total sales orders in 2021 were USD 1.73M, representing a 325% year-on-year growth.

Q4 sales orders in the ongoing US pilot program, launched in May 2021, totaled USD 325k, representing 27% growth over Q3 2021 and yielded a total sales order figure of USD 652k for the year.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6168/109227_6a045c9bd44c389a_006.jpg

VINIA® Sales Orders (USD) - by Country by Quarter Q4 2020 - Q4 2021

To view an enhanced version of this chart, please visit:
https://orders.newsfilecorp.com/files/6168/109227_6a045c9bd44c389a_006full.jpg

Moreover, sales and marketing metrics in the US point clearly to increasingly robust demand. Approximately 83% of 2020 sales and 89% of orders at www.vinia.com are derived from subscriptions packages with approximately 70% of subscriptions accounting for recurring payment packages of 3 months or more, demonstrating a significant opportunity to build a scalable, sustainable, and profitable business.

To continue to drive the company's leadership in global e-commerce and marketing, BioHarvest has hired Jared Turner as VP of Global E-Commerce. Turner, who joined in December, brings over 15 years of relevant leadership experience in building end-to-end Nutraceutical e-commerce businesses. Under his stewardship, the commercial team is poised to achieve further sales growth in VINIA® as well as other products that will be introduced in 2022, including Cannabis.

"I am very proud of the sales results achieved in the last quarter and for the entire year," said CEO, Ilan Sobel. "Combined with the scientific and technological accomplishments we posted, 2021 was an outstanding year. The sales and marketing team has demonstrated unique capabilities to successfully grow the business. We eagerly look forward to scaling our US pilot once our technology transfer to our new 20 ton/year VINIA® manufacturing facility is successfully completed, enabling us to reach optimal production levels. I anticipate another year of record sales in 2022, positively impacting the health and wellness of tens of thousands of satisfied customers."

BioHarvest further expanded the applicability of its proprietary technology in 2021, which allows it to harvest nutrients and active ingredients without growing plants, with the announcement in December that the Company had developed the capability to produce a meaningful amount - 10 kilograms - of full-spectrum Cannabis biomass without growing the plant itself.

In November, BioHarvest appointed renowned Canadian astronaut Chris Hadfield to its board of advisors as part of a drive to leverage its biotech technology platform to provide essential nutrition and active ingredients for space exploration and potential settlement in space.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that the Israeli market results will translate directly into the U.S. markets which may depend on different consumer preferences and more substantial marketing expenditures and resources. There is no assurance that strong sales metrics experienced to date will result in future demand or that proposed additional marketing expenditures will result in increased sales. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance, and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. There is no assurance that the ability to produce a commercial sized biomass will result in the Company entering into commercial production of Cannabis by H1 2022. There is no assurance of the imminent commissioning of the superfruit facility or the conversion of the two tons VINIA® facility to Cannabis production in the first half of 2022. These things are subject to construction and approval delays and uncertainties that may be beyond the control of BioHarvest. Projected sales of Cannabis will require the Company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Readers are cautioned that sales alone do not give an accurate picture of the financial position of the company and should be read in the context of the Company's annual and quarterly financial statements.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109227

Very nice post. I have been happy buying into and investing in this dream. It is great to see the techknowldgy used for nutrition and wellness products indeed, that portion of the plan makes it fun to tell my friends about… now to be honest, I was first drawn in by the use for recreational THC use also, and I know this was believed out here, the idea of a more pure, consistent, various strengths and types was exciting, and produced in a first ever way … in a startup I was lucky to be part of was/is extremely exciting, especially on the verge of the world getting it straight with the “laws”.

(Deep breath) now, however this is exciting. Another biz I have found, which we my knock on the door of, I wonder if you’r not already friends with them , under the symbol CANF ? There is allot going on out here,

we all have to remember one thing going forward…we vote with out wallets! I am just hitting 66 yr. And in the last couple years i have really been focused on what I eat, when I eat, supplements, Immunity…and I bet most of us investors are in that boat, for the long haul.

.please build US a business that I / WE can pass on to our children, a famially investment as it where.. I have been in food service all my life, now so are my children… one reason I am a little glade for waiting on the recreational area is avoiding becoming a “retail lottery grab”…a meme stock. Yup I do want to see a profit , why not,..I’m not in for the next amc/bit c excetera…
and if we can’t post a dividend why not a dividend in the form of a NFT good for 50% discount on a 3 mos supply of ( take your pick)..

For now I still get excited when I check the stocks price has stayed low so I can buy some more ha, ha, but it makes my day…and please look into that one I mentioned above..that is also super cool, or can be…

Thanks much for letting me rant, maybe I’ll be using some of our products in my bakery, let me know if you have something you want tested,

Al …freezing in Wisconsin ??

$CNVCF BioHarvest Sciences Inc. 2021 CEO Letter to Shareholder Partners
Press Release | 12/30/2021
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 30, 2021) - BioHarvest Sciences Inc. (CSE: BHSC) (OTC PINK: CNVCF) ("BioHarvest" or the "Company") is pleased to provide the following year-end shareholder partner letter from CEO Ilan Sobel.

Dear friends,

It is with great pleasure that I take this opportunity at the end of the year to summarize for our shareholder partners the major accomplishments of what has been an inspiring and transformative first full calendar year for me as CEO of BioHarvest Sciences. I will also include my own forward-looking thoughts for how we are envisioning the year ahead, in which we expect to trigger an acceleration of revenue growth, a game-changing expansion of our product lineup, as well as regulatory work and clinical studies that will provide a clear roadmap to continued global growth. Our vision is to drive human utility value: making a fundamental and positive change to our consumer's overall health and wellness. 2022 will be a year in which we not only open new doors as we further scale and commercialize our products, but also open minds to the significant potential that our platform technology has to drive this fundamental improvement in health and wellness on a global scale.

In accordance with BioHarvest's vision and its biotech journey, I am extremely proud to share below the team's 2021 achievements grouped by key areas: Science & Technology, Operations, Sales, Finance and Environmental & Social Governance.

2021 Achievements

Science & Technology

In August 2021, we announced the historical creation of the Amalgamated Trichomes Coral Structure (ATCS). Why was this so important? Because the way to deliver full spectrum cannabis is to grow the trichomes, which are the mini factories of the cannabis plant where all cannabinoids, flavonoids and terpenes are produced. These trichomes are delicate components of the plant which can be vulnerable to the shear forces applied by the motion of the liquid media in the bioreactors. This new coral structure protects the trichomes during their growth in such a way that has enabled us to move from lab-scale creation of the trichomes towards larger scale bioreactors.
We announced on December 8 that we were the first company in the world to grow a significant amount of cannabis biomass "without growing the plant", creating biotech and Cannabis industry history. With three different strains under development, we have now produced over 10 kilograms of biomass. The news has generated significant media interest (which I will detail below), and it has also introduced our science to thousands of new investors, science fans, and cannabis enthusiasts. It has provided a firm launch point for 2022, and there is more to come: I have challenged our marketing team to have the accompanying video viewed 1 million+ times, and we are already at 250,000+, so please stay tuned to our upcoming media placements!
Through our continued research, we added a new functionality claim for VINIA®, which reduces the oxidation of LDL cholesterol, enabling VINIA® to have one more important reason to appeal to the millions of consumers concerned about their cardiovascular health.
Operations

I am so proud that our new 20 Ton per year production facility was completed on schedule, passing the ISO audits in September 2021, despite significant global supply challenges. We received GMP certification from Israel's Ministry of Health in November and we are currently working hard to execute the biological technology transfer, so we can commence production.
Our Science, Advisory and Executive teams are critical for executing our biotech vision. This year we were honored to add both significant brain power and experience to each group with the addition of Colonel Chris Hadfield (space and aeronautics), Dr. Dennis Goodman (cardiology), Steven Lehrer (biotech), and Scott McCune (consumer marketing) to our Advisory Board. David Tsur (pharmaceutical and biotech) has joined the Board of Directors. Kobi Rosenzweig (VP operations) and Jarred Turner (VP of E-commerce) have joined the executive team. Building a world class company requires world class people - I am so pleased that each of these industry experts has joined us on our journey.
Sales

Israel Sales - This time last year we were energized by the spectacular VINIA Israel ecommerce launch in Q4 2020, which established a sales momentum that we have been able to successfully maintain. Throughout 2021, we continued to grow revenue in this market, at 10% sales growth quarter on quarter, for the first 3 quarters of the year, and accordingly have increased full year guidance on two occasions.
VINIA US Market launch - May 2021. While this highlight is only one of many from 2021, it represented a giant leap forward for BioHarvest Sciences. We created entirely new operational units to facilitate the workings of a successful North American e-commerce business, including Marketing, Fulfilment, Customer Success, and global supply. We also added the required thought leadership with committed staff and external partners to bring us their expertise and drive from Launch Day forward.
Sales performance in the U.S. pilot program has been extremely encouraging with us crossing the US$100,000 sales orders per month mark very early in the launch, with 89% of sales being subscription packages generating monthly recurring revenue, and an average sales order value of US $80 per transaction.

We have been humbled by the feedback from our consumer base - as of this week, new VINIA users have submitted 350+ verified reviews, with a 4.8/5 rating, which is best in class from a performance perspective when benchmarked versus industry norms.

We look forward to scaling our US launch as soon as we bring our new 20 Ton per year manufacturing facility online and to adding significant customer count to a base that already exceeds 11,000 customers across USA and Israel.

B2B Sales - our Batory sales and distribution partnership continues to add significant value for the business. We have successfully expanded our partnership with "Designs for Health Inc" who in 2021 formulated VINIA® into 3 new products which are now commercially available including "NRF2 Modulator", "Senolytic Synergy" and "Bergavin™". We are currently engaged in a number of strategic discussions with giants of industry and look forward to converting additional major B2B partnerships in 2022.
Finance

Investors have reacted positively to the company's achievements throughout 2021. The share price increased ~130% from the beginning of the year to reflect a recently reached market capitalization of ~$200 million.
Strong treasury - In 2021, we raised a total of $9.4 Million CAD in two successful private placements, plus $4.6 Million CAD in exercised warrants.
In 2021, we have significantly increased the investor base. As the company continues to perform well against its biotech vision and increases revenues substantially, the prospects remain high for 2022 to further increase that base and to add more institutional investors.
Given the 2021 achievements record and the 2022 prospects listed below, we believe that BioHarvest presents a very attractive investment opportunity.
Environmental & Social Governance

I trust that our community of investor partners understands how deeply we are committed to making BioHarvest Sciences a role model for other companies to follow as it relates to our ESG credentials and delivering continuous improvement across key identified metrics.

In July, we became the first Biotechnology company that produces cannabinoids to publish an ESG Sustainability report. This initial report was our first, and there are more to come. As the Globe and Mail reported on Dec 28. 2021, our BioFarming technology can reduce land requirements for nutrient growth by 95%. Investors are welcome to access the complete ESG report here.
We are a company committed to diversity in the workplace and understand the power of diversity to help create competitive advantage. We are very proud of the fact that 55% of our workforce is female and that our entire R & D team is female. Importantly, as a company that understands the power of experience, we have more than 45% of our workforce above the age of 50 years old. This provides us with a wealth of brain power, people maturity and a unique sense of drive and commitment to make the world better for our children and grandchildren.
Our December media coverage on cannabis R+D has generated a wave of commercial inquiries, which is fantastic, and we are committed to responding to every contact. I want to reassure investors that we will consider every commercial opportunity, but I do want our community to understand that our first priority will be to supply cannabis ingredients for medicinal applications in line with our commitment to be a purpose driven company. We do not envision replacing recreational suppliers, or artisan growers - we will focus on providing fingerprint consistent ingredients for products that require the highest levels of cleanliness and consistency.
Media Coverage

This year, we partnered with two very established public relations firms (Boldt and Thunder-11) to help introduce us to both Major news media and the cannabis community, and it has paid huge dividends in "earned" media coverage. For the portion of our community that follows early-stage companies, this major media interest will be mind blowing, as small companies will rarely make the news cycle. Our North American news coverage is spiking here at the end of 2021, which establishes a fantastic launching point for the New Year.

Forbes.com: Dec 8 - Producing Cannabis Biomass Without Growing A Cannabis Plant - How One Company Is Doing It.
The Globe and Mail: Dec. 28 - Canadian-Israeli biotech company growing nutrients for Earth and beyond
The Houston Chronicle: Dec. 27 - Bowie Singing Astronaut developing protein pills for real space travel
CannabisTech.com: Dec. 23 - How to Grow Cannabis Without Growing a Plant
The Jerusalem Post: Dec. 29 - An astounding 2021 for Israeli tech could bring pivot
Looking Forward to 2022

This coming year will see us "land" and "expand", plus drive further impact in existing programs.

We expect to be selling our first cannabis-related products in 2022 upon completion of our final scale up phase and regulatory approvals. For VINIA, we are planning a step up in aggressive US marketing and will continue to push forward on the regulatory approval of VINIA in the EU and UK. As a science-based company, we always want to expand our science-based credentials, so we intend to fund additional clinical trials on VINIA, cannabis, and our olive cell product which is next in our polyphenol/antioxidant pipeline.

At some point in the first half of 2022, we will likely announce the next plant-based vertical which we believe we can disrupt with our proprietary platform technology, adding one more significant validation on how we can bring the power of the plant to the people. Investors can also anticipate the 2022 launch of our first cannabis products and the significant scaling of VINIA®. I expect these two products to generate market-moving revenues in 2022, but they are just the start.

We will also join the space race as the likes of Elon Musk, Jeff Bezos, and Sir Richard Branson work to make "space settlements" something of a reality by 2030. We will work closely with our new advisory board member Colonel Chris Hadfield to start the process to assess how we can use our proprietary platform to help solve two major challenges which exists for space settlements - sustainable food supply and reducing the effects of ionizing radiation on oxidation of LDL cholesterol.

Our entire team is so thankful that you have been part of this stage in our growth phase, and we are very proud to partner with you on our biotech journey. We are inspired by your support and the deep sense of "purpose" that you share with us on the BioHarvest Sciences team. That primary purpose is to drive Human Utility Value, and to drive a transformational positive change in the Health and Wellness of hundreds of millions of people.

Our team is laser focused on executing the 2022 plan, and we intend to make 2022 a year to remember.

For a video reel of this year's major announcements, click here.

Happy New Year and may your 2022 be filled with only good health and blessings.

Warmest wishes,

Ilan Sobel, Chief Executive Officer
BioHarvest Sciences Inc.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
Youtube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets including bio-space and exposing our technology to different verticals. In particular, there is no assurance that the Company will be able to leverage its technology platform to successfully provide essential nutrition and active ingredients for space exploration. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. There is no assurance that the ability to produce a commercial sized biomass will result in the Company entering into commercial production of Cannabis. There is no assurance the Company will be able to successfully convert the exiting 2 tons/year VINIA® facility to a Cannabis production facility in H1, 2022. There is no assurance we will be able to commercialize our first Cannabis products in the first half of 2022, and there is no assurance the Company will be able to add new verticals or build additional plants elsewhere. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. There is no assurance that the Israeli market results for Vinia® will translate directly into the U.S. markets which may depend on different consumer preferences and more substantial marketing expenditures and resources. There is no assurance that strong sales metrics experienced to date will result in future demand for VINIA®. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.

There is no assurance we will trigger an acceleration of revenue growth or a game changing expansion of our product lineup. These things are subject to uncertainties including the uncertainty of continuing market acceptance of our products and market acceptance of new products which are subject to changing consumer preference and access to marketplaces. There is no assurance we will achieve additional major B2B partnerships in 2022 as this is subject to acceptance of our products by businesses and their customers. There is no assurance that we will increase our investor base or add new institutional investors as this is subject to our meeting investment criteria of investors and conditions affecting equity markets generally. Continuing outbreaks of Covid variants may cause delays or other impacts to business plans and /or impact equity markets in 2022.

All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

I do not know if this has been posted here yet
https://www.cannabistech.com/articles/how-to-grow-cannabis-without-growing-a-plant/?fbclid=IwAR2HUOqoNrTJPyuBneNYY4VVCWMzbFt5KT1XuFShOqz3pCzC9pExjda0GuY

I vote with my dollar for a better world. If I do not help people with a good idea make it happen who will? That is the reason I am so focused on the cannabis sector is that this stuff is such a healing medicine that has been used as food and wellbeing for aeons and it was made “ illegal” for the benefit of chemical companies and timber barons. This grows more paper per acre faster than timber does. It cures many things including intractable epilepsy in children and the govt still treats it like a toxin! Even though there has never been a death attributed to this plant. The only way it changes is if we common folks make it happen! I will take a look at your suggestion. Cannabis is a food, a medicine and a fibre. There is a canadian man named Rick Simpson who cured cancer in people who were sent home to die by the medical systems (I am not anti doctor!) and fir his trouble he was harassed by the rcmp to the point he left and now lives in exile! They took his records and now lo and behold we have a bunch of ex police in line at the money trough. We need research, and investment in wellbeing that comes from natural sources and this project is a hybrid. Purity is needed when people rely on a medicine and this seems to fit the bill. Outdoor grown has many qualities but it can have molds and such that are hard to manage. Pesticides do not work, because it is used “raw”, you can not heat it without changing it and you can not wash it because it knocks off the active ingredient, the trichomes. This system seems to solve those problems and it may be able to produce rare cannabanoids at scale such exciting times ahead.

My last post has a mistake..I mentioned a (Phpi), should be ..PHBI…??

Al..happy hunting.

The only thing I have found that comes close in the ag space, and is adaptable to ,”not only hemp/mj” is PHPI. (Talking high tech and highly focused).. it’s all really wild what’s going on really. The whole agriculture space is changing and much is doable for the smallest of us to the biggies of us :) every one of us needs to start growing “anything”, and investing in the best entrepreneurs we can find…not just the next 100 x-er we can hit and run on! Steady long term companies need some steady long term investors… ha…my Pennie’s worth??

Al.

I have been in the legal cannabis space since 2015. This is a game changer. I love the fact they are already producing the red grape products (I want to get some of that too!) but cannabis is the next “big thing”. I am very familiar with the challenges of growing at scale and it is challenging to say the least and achievable by very few. This will provide the clean and consistent input for nutraceuticals and CPG products. So excited because this medicine is incredible and we need more of it in the world. Such an exciting time to be alive!

My fav. Holding...to me this is the sleeper of the decade. It is one of those overnight sensations now years in the making..;)